Risk in Vaccine Research and Development Quantified

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Pronker, Esther S ^a,b   Weenen, Tamar C ^b   Commandeur, Harry ^b   Claassen, Eric H J H M ^c,d   Osterhaus, Albertus D M E ^d  

^a Vacceleron   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ENCEVAC; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; JEEV; MALARIA VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHRAX; ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG RESEARCH; GOVERNMENT; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFLUENZA; JAPANESE ENCEPHALITIS; MALARIA; PANDEMIC INFLUENZA; RISK ASSESSMENT; RISK FACTOR; VACCINATION; VACCINE PRODUCTION;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; RISK; TIME FACTORS; VACCINATION; VACCINES;

EID: 84875124377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057755     Document Type: Article

References (39)

1. Andre F, (2001) Short Survey: the Future of Vaccines, Immunization Concepts and Practices. Vaccine 19: 2206-2209.
2. Armstrong G, Conn L, Pinner R, (1999) Trends in Infectious Disease Mortality in the US During the 20th Century. Journal of American Medical Association 281: 61-66.
3. Davis M, Butchart A, Coleman M, Singer D, Wheeler J, et al. (2010) The Expanding Vaccine Pipeline, 1995-2008. Vaccine 28: 1353-1356.
4. Ulmer B, Valley U, Rappuoli R, (2006) Vaccine manufacturing; Challenges and solutions. Nature Biotechnology 24: 1377-1383.
5. Andre F, (2002) How the Research-based Industry Approaches Vaccine Development and Establishes Priorities. Developments in Biology 110: 25-29.
6. Kieny M, Girard M, (2005) Human Vaccine R&D. Vaccine 23: 5705-5707.
7. Riley S, (2008) The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to it. rbhc0214.
8. US Department of Health and Human Services, FDA (2004) Challenge and opportunity on the critical path to new medicinal products.
9. Carney S, (2005) How Can We Avoid the Productivity Gap? Drug Discovery Today 10: 1011-1013.
10. Sahoo A, (2008) Drug Approval Trends at the FDA and EMEA: Process Improvement, Heightened Scrutiny and Industry Response. pp. BI00027-012.
11. Pronker E, Weenen T, Commandeur H, Osterhaus A, Claassen E, (2011) The Gold Industry Standard for Risk and Cost of Drug and Vaccine Development Revisited. Vaccine 29: 5846-5849.
12. Struck M, (1996) Vaccine R&D Success Rates and Development Times. Nature Biotechnology 14: 591-593.
13. Dimasi J, Grabowski H, (2007) The Cost of Biopharmaceutical R&D: is Biotech Different? Managerial and Decision Economics 28: 469-479.
14. Kola I, Landis J, (2004) Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery 3: 711-715.
15. Dimasi J, Hansen R, Grabowski H, (2003) The price of innovation; new estimates of drug development costs. Journal of Health Economics 22: 185.
16. Davis M, Butchart A, Wheeler J, Coleman M, Singer D, et al. (2011) Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine 29: 9414-9416.
17. Dimasi J, Feldman L, Seckler A, Wilson A, (2010) Trends and Risks Associated With New Drug Development: Success Rates for Investigational Drugs. Nature Clinical Pharmacology and Therapeutics 87: 272-277.
18. Collin N, Radiguez Xd, (2009) Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 27: 5184-5186.
19. Data Monitor Business Intelligence (2009) Commercial Insight: Influenza Vaccines and Antivirals- a Pandemic's long-term impact. DMHC2516.
20. Jennings L, Monto A, Chan P, Szucs T, Nicholson K, (2008) Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infectious Disease 8: 650-658.
21. European Commission (2009) Commission staff working document on join procurement of vaccine against influenza A (H1N1).
22. European Commission (2011) Joint procurement agreement to procure common auction platforms.
23. Arrowsmith J, (2011) Trial Watch: Phase II Failure 2008-2010. Nature Reviews Drug Discovery 10: 1.
24. Berthold D, Gulamhusein A, Jackson J, Tannock I, (2009) The Transition from Phase II to Phase III Studies. Journal of Clinical Oncology 27: 1150-1151.
25. Bunnage M, (2011) Getting Pharmaceutical R&D Back on Track. Nature Chemical Biology 7: 335-339.
26. Arrowsmith J, (2011) Trial Watch: Phase III and Submission Failure 2007-2010. Nature Reviews Drug Discovery 10: 1.
27. Archibugi D, Bizzarri K, (2004) Committing to Vaccined R&D: a global science policy priority. Research Policy 33: 1657-1671.
28. Cunha B, (2002) Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room. Clinical Microbiology Infection 8: 489-503.
29. Pronker E, Claassen E, Osterhaus A, (2012) Development of new generation influenza vaccines; Recipes for success? Vaccine 30: 7344-7347.
30. Danzon M, Nicholson S, Pereire N, (2005) Productivity in the Pharmaceutical and Biotechnology R&D: the Role of Experiences and Alliances. Journal of Health Economics 24: 317-339.
31. Lou K, Rond M, (2006) From the Analyst's Couch: the 'Not Invented Here' Myth. Nature Reviews Drug Discovery 5: 451-452.
32. Jacobs P, Ohinmaa A, (2010) A Comparison of the Use of Economics in Vaccine Expert Reviews. Vaccine 28: 2841-2845.
33. Light D, Andrus J, Warburton R, (2009) Estimated Research and Development Costs of Rotavirus Vaccines. Vaccine 27: 6627-6633.
34. Data Monitor Business Intelligence (2009) Big Pharma Performance Before, During and Beyond the Global Recession; A comparative analysis of leading pharmaceutical company sales dynamics over the period 2005-14. DMHC2582.
35. WHO website. Influenza: Seasonal Fact Sheet. Available: http://www.who.int/mediacentre/factsheets/fs211/en/index.html. Accessed 2010 Aug 26.
36. WHO website. HIV/AIDS: Facts on HIV/AIDS. Available: http://www.who.int/hiv/data/en/index.html. Accessed 2010 Dec 6.
37. Who website. Media Centre: Hepatitis B. Available:http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed 2010 Dec 12.
38. WHO website. Media Centre: Malaria. Available: http://www.who.int/mediacentre/factsheets/fs094/en/index.html. Accessed 2010 Dec 6.
39. WHO website. Vector-borne viral infectious disease. Available: http://www.who.int/vaccine_research/diseases/vector/en/index2.html. Accessed 2012 Mar 5.